Clinical EfficacyDespite the attractive setup, follow-up will likely be too immature to assess durability.
Financial PerformanceNet loss of $21.2 million, or a loss of $0.35 per share, was comparable to the projected loss, indicating financial challenges.
Investor SentimentPYXS’s persistent underperformance and negative EV evidently reflects continued investor skepticism of micvo’s opportunity in SCCHN.